Default company panoramic image
Logo small

RJSBio, Inc.

RJSBio is developing “tethered addressed” non-peptide small-molecules for the treatment of cancer and inflammatory conditions.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded February 2009
  • Employees 8
  • Website rjsbiologics.com

Company Summary

A cancer drug’s journey to its intended target is a key component to its ultimate success or failure. At RJSBio we define the path of a cancer drug to, and within, a cancer cell using fully-synthetic drug conjugates.

Our modular small-molecule approach leads to efficient uptake of toxic conjugates specifically by cancer cells. Our design minimizes unwanted uptake of these drugs by normal cells, where harmful side effects are manifested.

Team

  • Default avatar
    Stephen M. McCraith, PhD
    Founder/CSO

    2009-Current Founder/CSO, RJS Biologics, LLC. Seattle, WA

    2006-2009 Senior Scientist, Ameritech Inc., Millcreek, WA
    Development of Diagnostic Tests for HIV and Cancer.

    2006-2006 Senior Scientist, Allozyne Inc.
    Inventor of AZ01, Allozyne's lead MS biological currently in Phase I/II.

    2004-2006 Senior Scientist I, Albany Molecular Research, Bothell WA
    Assay development/screening a 500,000 member natural product library.

  • Default avatar
    6 Members - List available upon request
    Scientific Advisors,

    RJS Bio has a team of talented and renowned scientific advisers that it prefers to not disclose on this public website. These advisers bring a wealth of talent in the areas of organic chemistry, in silico drug design, pharmacology, in vivo cancer models as well as experience in small molecule and biological development.

Advisors

  • Default avatar
    Jeffrey Oster, Ph.D.,J.D
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    RJS Biologics has been personally funded while in stealth mode.
    Unconfirmed
    Default avatar
    We are now seeking outside funding through investments and SBIR funding.
    Unconfirmed